High efficacy of onabotulinumtoxinA treatment in patients with comorbid migraine and depression: a meta-analysis
Abstract Background Migraine and depression are highly prevalent and partly overlapping disorders that cause strong limitations in daily life. Patients tend to respond poorly to the therapies available for these diseases. OnabotulinumtoxinA has been proven to be an effective treatment for both migra...
Main Authors: | Oreste Affatato, Thiago C. Moulin, Claudia Pisanu, Victoria S. Babasieva, Marco Russo, Elif I. Aydinlar, Paola Torelli, Vladimir N. Chubarev, Vadim V. Tarasov, Helgi B. Schiöth, Jessica Mwinyi |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2021-03-01
|
Series: | Journal of Translational Medicine |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12967-021-02801-w |
Similar Items
-
OnabotulinumtoxinA for chronic migraine during pregnancy: a real world experience on 45 patients
by: Ho-Tin Wong, et al.
Published: (2020-10-01) -
Economic consequences of migraine in Sweden and implications for the cost-effectiveness of onabotulinumtoxinA (Botox) for chronic migraine in Sweden and Norway
by: Amanda Hansson-Hedblom, et al.
Published: (2020-08-01) -
Sustained onabotulinumtoxinA therapeutic benefits in patients with chronic migraine over 3 years of treatment
by: Michail Vikelis, et al.
Published: (2018-09-01) -
Improvements in pain, medication use and quality of life in onabotulinumtoxinA-resistant chronic migraine patients following erenumab treatment – real world outcomes
by: J. Talbot, et al.
Published: (2021-01-01) -
Guideline on the use of onabotulinumtoxinA in chronic migraine: a consensus statement from the European Headache Federation
by: Lars Bendtsen, et al.
Published: (2018-09-01)